Nothing's perfect: the art of defining HLA-specific antibodies.

[1]  L. Chatenoud,et al.  Outcome of Kidney Transplantations Performed With Preformed Donor‐Specific Antibodies of Unknown Etiology , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  J. Pascual,et al.  Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? , 2013, Transplant immunology.

[3]  D. Roelen,et al.  Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients. , 2013, Tissue antigens.

[4]  M. Zeier,et al.  Influence of Test Technique on Sensitization Status of Patients on the Kidney Transplant Waiting List , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  R. Bray,et al.  In Search of Perfection , 2013, American Journal of Transplantation.

[6]  R. Bray,et al.  Technical aspects of HLA antibody testing , 2013, Current opinion in organ transplantation.

[7]  P S Heeger,et al.  Comprehensive Assessment and Standardization of Solid Phase Multiplex‐Bead Arrays for the Detection of Antibodies to HLA , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  P. Szatmary,et al.  Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1 year , 2013, Clinical kidney journal.

[9]  A. Webster,et al.  Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation , 2013, Transplantation.

[10]  R. Higgins,et al.  Human Leukocyte Antigen Antibody-Incompatible Renal Transplantation: Excellent Medium-Term Outcomes With Negative Cytotoxic Crossmatch , 2011, Transplantation.

[11]  D. Tyan,et al.  Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. , 2011, Human immunology.

[12]  J. Cecka,et al.  Calculated PRA: Initial Results Show Benefits for Sensitized Patients and a Reduction in Positive Crossmatches , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  L. Sharples,et al.  Ten-Year Experience of Selective Omission of the Pretransplant Crossmatch Test in Deceased Donor Kidney Transplantation , 2010, Transplantation.

[14]  P. Nickerson,et al.  64-P: Solid phase PRA (SPP) testing identifies patients whose positive initial T cell XM cannot be explained on the basis of HLA A,B,C,DR,DQ antibodies (Ab) , 2009 .

[15]  A. Tambur,et al.  41-OR: The DQ dichotomy; to V or not to V (virtual XM) , 2009 .

[16]  P. Terasaki,et al.  Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. , 2009, Human immunology.

[17]  J. Bradley,et al.  Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. , 2009, Human immunology.

[18]  Jeffrey T. Sholander,et al.  Using real data for a virtual crossmatch. , 2009, Human immunology.

[19]  G. Russ,et al.  Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. , 2009, Human immunology.

[20]  T. Mohanakumar,et al.  Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. , 2009, Human immunology.

[21]  V. D’Agati,et al.  Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. , 2009, Human immunology.

[22]  F. Claas,et al.  Human leukocyte antigen antibody detection and kidney allocation within Eurotransplant. , 2009, Human immunology.

[23]  M. Christiaans,et al.  Donor-Directed HLA Antibodies Before and After Transplantectomy Detected by the Luminex Single Antigen Assay , 2009, Transplantation.

[24]  P. Terasaki,et al.  “Natural” Human Leukocyte Antigen Antibodies Found in Nonalloimmunized Healthy Males , 2008, Transplantation.

[25]  M. Stegall,et al.  The Spectrum of Antibody‐Mediated Renal Allograft Injury: Implications for Treatment , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  L. Sharples,et al.  Predicting the Immunogenicity of Human Leukocyte Antigen Class I Alloantigens Using Structural Epitope Analysis Determined by HLAMatchmaker , 2008, Transplantation.

[27]  K. Nelson,et al.  25-P: HLA density on microparticles versus antibody detection sensitivity: Implications for crossmatch prediction , 2007 .

[28]  F. Dominici,et al.  Outcomes of Kidneys from Donors After Cardiac Death: Implications for Allocation and Preservation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  Steven G.E. Marsh,et al.  Nomenclature for factors of the HLA system, update November 2006. , 2007 .

[30]  Rene J Duquesnoy,et al.  A structurally based approach to determine HLA compatibility at the humoral immune level. , 2006, Human immunology.

[31]  R. Montgomery,et al.  Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. , 2005, Human immunology.

[32]  J. Buckels,et al.  HLA incompatible combined liver-kidney transplantation: dynamics of antibody modulation revealed by a novel approach to HLA antibody characterisation. , 2014, Transplant immunology.

[33]  J. Lunz,et al.  Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[34]  P. Terasaki,et al.  Epitopes of HLA-A, B, C, DR, DQ, DP and MICA antigens. , 2009, Clinical transplants.

[35]  D. Middleton,et al.  One thousand renal transplants in Belfast (1968-1998). , 2004, Clinical transplants.